申请人:MEDIVIR AB
公开号:WO2005065689A1
公开(公告)日:2005-07-21
Deoxyuridine derivatives of the formula (I) where R1 is H or various substituents; D is -NHCO-, -CONH-, -0-, -C(=O)-, -CH=CH, -CΞC-, -NR5-; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is -O-, -S-, -CHR10-, -C(=O)-; J is -CH2-, or when G is CHR10 may also be -O- or -NH-; R10 is H, F, -CH3, -CH2NH2, -CH2OH; -OH R11 is H, F, -CH3, -CH2 NH2, -CH2OH, CH(OH)CH3, CH(NH3)CH3; or R10 and R11 together define an olefinic bond, or together form a -CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.
脱氧尿嘧啶衍生物的公式(I),其中R1是H或不同的取代基;D是-NHCO-,-CONH-,-0-,-C(=O)-,-CH=CH,-CΞC-,-NR5-;R4是氢或不同的取代基;R5是H,C1-C4烷基,C1-C4烷酰基;E是Si或C;R6、R7和R8独立地选自C1-C8烷基,C2-C8烯基,C2-C8炔基或稳定的单环、双环或三环环系;G是-O-,-S-,-CHR10-,-C(=O)-;J是-CH2-,或者当G是CHR10时,也可以是-O-或-NH-;R10是H,F,-CH3,-CH2NH2,-CH2OH;-OH R11是H,F,-CH3,-CH2 NH2,-CH2OH,CH(OH)CH3,CH(NH3)CH3;或者R10和R11共同定义一个烯丙基键,或者共同形成一个-CH2-基团,从而定义一个顺式或反式环丙基基团;在预防或治疗疟疾等原虫性疾病方面具有用途。